父亲的偏见 donepezil 暴露可以提高后代的学习能力
Guangyuan Fan1, Tao Pan1, Xingyu Ji1
1School of Basic Medical Sciences, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai, 200032, China.
Behavioral and brain functions : BBF
|September 28, 2024
概括
父亲使用增强认知功能的药物多尼佩西尔 (donepezil),可能会改善后代的学习和记忆. 这项对大鼠的研究表明,通过非神经通路可以获得潜在的益处,因此需要进一步调查.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 父母使用向中枢神经系统的药物可能会影响后代的发育.
- 多尼西尔是一种胆酶抑制剂,可以增强认知能力.
- 父亲暴露于多尼佩西尔对后代的影响尚未被探索.
研究的目的:
- 为了研究父亲给予多尼佩西尔对后代学习和记忆的影响.
- 探索这些影响背后的潜在分子机制.
主要方法:
- 雄性大鼠在繁殖前21天接受了口服多尼佩西尔 (4毫克/公斤).
- 后代 (F1代) 通过行为测试 (新物体识别,Y迷宫,操作学习) 进行评估.
- 对海马组织进行了转录组分析.
主要成果:
- 父亲暴露于多尼佩西尔在男性和女性F1后代中增强了学习和短期记忆.
- 转录组分析揭示了F1海马体中细胞外矩阵相关基因的变化.
- 确定了与智力相关的潜在核心基因.
结论:
- 父亲接触多尼佩西尔可能会增强后代的认知能力.
- 该机制可能涉及大脑中的非神经,细胞外点.
- 需要进一步的研究来证实跨代效应.
相关概念视频
Long-term Potentiation
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Long-term Potentiation
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when presynaptic neurons...
Hebbian LTP
LTP can occur when presynaptic neurons...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...


